**Supplementary information**

**Obesity and Impaired Metabolic Health Increase Risk of COVID-19-Related Mortality in Young and Middle-Aged Adults to the Level Observed in Older People: the LEOSS Registry**

Norbert Stefan, MD1,2,3\* Katrin Sippel, PhD1,2,3\* Martin Heni,PhD1,2,3 Andreas Fritsche, PhD1,2,3 Robert Wagner, PhD1,2,3 Carolin E. M. Jakob,4,5 Hubert Preißl, PhD1,3 Alexander von Werder, MD5,6 Yascha Khodamoradi, MD7 Stefan Borgmann, MD8 Maria Madeleine Rüthrich, MD9 Frank Hanses, MD10 Martina Haselberger, MD11 Christiane Piepel, MD12 Martin Hower, MD13 Juergen vom Dahl, MD14 Kai Wille, MD15 Christoph Römmele, MD16 Janne Vehreschild, MD3,4,17 Melanie Stecher,4,5 Michele Solimena, PhD3,18 Michael Roden, MD3,19,20 Annette Schürmann, PhD3,21 Baptist Gallwitz, MD2 Martin Hrabe de Angelis, PhD3,22 David S. Ludwig, MD23 Matthias B. Schulze, DrPH3,24 Bjoern Erik Ole Jensen, MD25# Andreas L. Birkenfeld, MD1,2,3# on behalf of the LEOSS Study Group

**Suppl. Table 1.** Characteristics of the patients with COVID-19

| **Characteristics** | **Category** | **Recovered** | **Died** |
| --- | --- | --- | --- |
|  |  | 2661 (84.13 %) | 502 (15.87 %) |
| **Age** |  |  |  |
|  | Age 18-25 | 71 (100 %) | 0 (0 %) |
|  | Age 26-35 | 199 (98.51 %) | 3 (1.49 %) |
|  | Age 36-45 | 290 (98.64 %) | 4 (1.36 %) |
|  | Age 46-55 | 475 (94.81 %) | 26 (5.19 %) |
|  | Age 56-65 | 578 (87.44 %) | 83 (12.56 %) |
|  | Age 65-75 | 446 (79.79 %) | 113 (20.21 %) |
|  | Age 76-85 | 478 (73.88 %) | 169 (26.12 %) |
|  | Age >85 | 124 (54.39 %) | 104 (45.61 %) |
| **Sex** |  |  |  |
|  | Male | 1602 (82.88 %) | 331 (17.12 %) |
|  | Female | 1059 (86.1 %) | 171 (13.9 %) |
| **BMI** |  |  |  |
|  | 18.5 -24.9 | 873 (83.94 %) | 167 (16.06 %) |
|  | 25 - 29.9 | 977 (84.59 %) | 178 (15.41 %) |
|  | 30 - 34.9 | 534 (85.03 %) | 94 (14.97 %) |
|  | >= 35 | 277 (81.47 %) | 63 (18.53 %) |
| **Diabetes Status** |  |  |  |
|  | No diabetes | 2119 (86.42 %) | 333 (13.58 %) |
|  | Diabetes | 542 (76.23 %) | 169 (23.77 %) |
| **Diabetes Type** |  |  |  |
|  | Diabetes type 1 | 17 (89.47 %) | 2 (10.53 %) |
|  | Diabetes type 2 | 497 (76.46 %) | 153 (23.54 %) |
| **Diabetes Duration** |  |  |  |
|  | < 1 year | 15 (88.24 %) | 2 (11.76 %) |
|  | 1 -10 years | 67 (75.28 %) | 22 (24.72 %) |
|  | > 10 years | 73 (71.57 %) | 29 (28.43 %) |
|  | unknown | 2506 (84.81 %) | 449 (15.19 %) |
| **Diabetes Treatment** |  |  |  |
|  | Insulin | 174 (76.32 %) | 54 (23.68 %) |
|  | Metformin | 204 (83.27 %) | 41 (16.73 %) |
|  | Sulfonylureas | 17 (89.47 %) | 2 (10.53 %) |
|  | GLP-1-Analogs | 20 (83.33 %) | 4 (16.67 %) |
|  | DPP4-Inhibitors | 53 (79.1 %) | 14 (20.9 %) |
|  | SGLT2-Inhibitors | 34 (82.93 %) | 7 (17.07 %) |
| **HbA1c** |  |  |  |
|  | <6.4 | 48 (88.89 %) | 6 (11.11 %) |
|  | 6.4 - 8 % | 118 (81.38 %) | 27 (18.62 %) |
|  | 8.1 - 10% | 61 (81.33 %) | 14 (18.67 %) |
|  | >10% | 30 (71.43 %) | 12 (28.57 %) |
|  | not available | 2404 (84.44 %) | 443 (15.56 %) |
| **Hypertension** |  |  |  |
|  | yes | 1245 (77.38 %) | 364 (22.62 %) |
|  | no | 1416 (91.12 %) | 138 (8.88 %) |
|  |  |  |  |
| **Coronary Artery Disease** |  |  |  |
|  | yes | 321 (71.81 %) | 126 (28.19 %) |
|  | no | 2340 (86.16 %) | 376 (13.84 %) |
| **Chronic Kidney Disease** |  |  |  |
|  | yes | 339 (70.33 %) | 143 (29.67 %) |
|  | no | 2322 (86.61 %) | 359 (13.39 % |
| **Chronic Liver Disease** |  |  |  |
|  | yes | 55 (74.32 %) | 19 (25.68 %) |
|  | no | 2606 (84.36 %) | 483 (15.64 %) |
| **Liver Cirrhosis** |  |  |  |
|  | yes | 18 (66.67 %) | 9 (33.33 %) |
|  | no | 2643 (84.28 %) | 493 (15.72 %) |
| **CRP** |  |  |  |
|  | < 3 mg/L | 286 (96.95 %) | 9 (3.05 %) |
|  | 3- 29 mg/L | 732 (91.04 %) | 72 (8.96 %) |
|  | 30 - 69 mg/L | 343 (82.25 %) | 74 (17.75 %) |
|  | 70 - 119 mg/L | 263 (77.13 %) | 78 (22.87 %) |
|  | 120 - 179 mg/L | 160 (72.73 %) | 60 (27.27 %) |
|  | 180 - 249 mg/L | 68 (64.76 %) | 37 (35.24 %) |
|  | > 249 mg/L | 41 (53.25 %) | 36 (46.75 %) |
|  | not available | 768 (84.96 %) | 136 (15.04 %) |
| **IL6** |  |  |  |
|  | < 1.8 pg/mL | 25 (92.59 %) | 2 (7.41 %) |
|  | 1.8 - 49 pg/mL | 430 (95.56 %) | 20 (4.44 %) |
|  | 50 - 199 pg/mL | 184 (76.03 %) | 58 (23.97 %) |
|  | 200 - 499 pg/mL | 30 (49.18 %) | 31 (50.82 %) |
|  | 500 - 999 pg/mL | 5 (31.25 %) | 11 (68.75 %) |
|  | >1000 pg/mL | 8 (34.78 %) | 15 (65.22 %) |
|  | not available | 1979 (84.43 %) | 365 (15.57 %) |
| **Serum-Creatinine** |  |  |  |
|  | Normal | 1337 (90.4 %) | 142 (9.6 %) |
|  | >ULN | 357 (71.69 %) | 141 (28.31 %) |
|  | >2x ULN | 92 (63.01 %) | 54 (36.99 %) |
|  | >5x ULN | 29 (60.42 %) | 19 (39.58 %) |
|  | >10x ULN | 11 (100 %) | 0 (0 %) |
|  | not available | 835 (85.12 %) | 146 (14.88 %) |
| **AST** |  |  |  |
|  | Normal | 1002 (87.28 %) | 146 (12.72 % |
|  | >ULN | 442 (80.66 %) | 106 (19.34 %) |
|  | >2x ULN | 114 (76 %) | 36 (24 %) |
|  | >5x ULN | 13 (61.9 %) | 8 (38.1 %) |
|  | >10x ULN | 1 (14.29 %) | 6 (85.71 %) |
|  | >20x ULN | 2 (50 %) | 2 (50 %) |
|  | not available | 1087 (84.59 %) | 198 (15.41 %) |
| **ALT** |  |  |  |
|  | Normal | 1223 (84.05 %) | 232 (15.95 %) |
|  | >ULN | 358 (87.32 %) | 52 (12.68 %) |
|  | >2x ULN | 73 (80.22 %) | 18 (19.78 %) |
|  | >5x ULN | 12 (63.16 %) | 7 (36.84 %) |
|  | >10x ULN | 0 (%) | 0 (%) |
|  | >10x ULN | 0 (%) | 0 (%) |
|  | not available | 995 (83.75 %) | 193 (16.25 %) |
| **GGT** |  |  |  |
|  | Normal | 992 (87.02 %) | 148 (12.98 %) |
|  | >ULN | 334 (83.92 %) | 64 (16.08 %) |
|  | >2x ULN | 177 (78.32 %) | 49 (21.68 %) |
|  | >5x ULN | 40 (68.97 %) | 18 (31.03 %) |
|  | >10x ULN | 14 (42.42 %) | 19 (57.58 %) |
|  | >20x ULN | 0 (%) | 0 (%) |
|  | not available | 1104 (84.4 %) | 204 (15.6 %) |

**Suppl. Table 2.** Univariable relationships of anthropometrics, comorbidities and laboratory parameters with COVID-19-related mortality

| **Characteristics** | **OR** | **Lower 95% CI** | **Upper 95% CI** | **p** |
| --- | --- | --- | --- | --- |
| Age 18-25 years | 0.00 | 0.0000 | 0.0000 | 0.97 |
| Age 26-35 years (ref) |  |  |  |  |
| Age 36-45 years | 0.91 | 0.20 | 4.69 | 0.91 |
| Age 46-55 years | 3.63 | 1.26 | 15.35 | 0.036 |
| Age 56-65 years | 9.53 | 3.52 | 39.1 | 0.0001 |
| Age 66-75 years | 16.8 | 6.24 | 68.8 | <0.0001 |
| Age 76-85 years | 23.5 | 8.77 | 95.7 | <0.0001 |
| Age >85 years | 55.6 | 20.4 | 229 | <0.0001 |
| Sex female (ref) |  |  |  |  |
| Sex male | 1.28 | 1.05 | 1.57 | 0.016 |
| BMI 18.5 - 24.9 (kg∙m-2) (ref) |  |  |  |  |
| BMI 25 - 29.9 (kg∙m-2) | 0.95 | 0.76 | 1.20 | 0.68 |
| BMI 30 - 34.9 (kg∙m-2) | 0.92 | 0.70 | 1.21 | 0.55 |
| BMI ≥35 (kg∙m-2) | 1.19 | 0.86 | 1.63 | 0.29 |
| No diabetes (ref) |  |  |  |  |
| Diabetes | 1.98 | 1.61 | 2.44 | <0.0001 |
| No Hypertension (ref) |  |  |  |  |
| Hypertension | 3.00 | 2.44 | 3.71 | <0.0001 |
| No Coronary Artery Disease (ref) |  |  |  |  |
| Coronary Artery Disease | 2.44 | 1.93 | 3.08 | <0.0001 |
| No Chronic Kidney Disease (ref) |  |  |  |  |
| Chronic Kidney Disease | 2.73 | 2.18 | 3.41 | <0.0001 |
| No Chronic Liver Disease (ref) |  |  |  |  |
| Chronic Liver Disease | 1.86 | 1.07 | 3.11 | 0.021 |
| No Liver Cirrhosis (ref) |  |  |  |  |
| Liver Chirrhosis | 2.68 | 1.14 | 5.85 | 0.017 |
| No Insulin (ref) |  |  |  |  |
| Insulin | 1.78 | 1.28 | 2.44 | 0.0005 |
| Insulin unknown | 3.27 | 1.84 | 5.67 | <0.0001 |
| No Metformin (ref) |  |  |  |  |
| Metformin | 1.07 | 0.75 | 1.50 | 0.70 |
| No Sulfonylureas (ref) |  |  |  |  |
| Sulfonylureas | 0.62 | 0.10 | 2.18 | 0.53 |
| No GLP-1-Analogs(ref) |  |  |  |  |
| GLP-1-Analogs | 1.06 | 0.31 | 2.82 | 0.91 |
| No DPP4-Inhibitors (ref) |  |  |  |  |
| DPP4-Inhibitors | 1.41 | 0.75 | 2.49 | 0.26 |
| No SGLT2-Inhibitors (ref) |  |  |  |  |
| SGLT2-Inhibitors | 1.09 | 0.44 | 2.33 | 0.83 |
| HbA1c <6.4% (ref) |  |  |  |  |
| HbA1c 6.4% - 8% | 1.83 | 0.75 | 5.15 | 0.21 |
| HbA1c 8.1% - 10% | 1.84 | 0.68 | 5.51 | 0.25 |
| HbA1c >10% | 3.20 | 1.12 | 10.0 | 0.035 |
| HbA1c not available | 1.47 | 0.68 | 3.86 | 0.37 |
| CRP <3 mg/L (ref) |  |  |  |  |
| CRP 3 - 29 mg/L | 3.13 | 1.63 | 6.79 | 0.002 |
| CRP 30 - 69 mg/L | 6.86 | 3.55 | 14.9 | <0.0001 |
| CRP 70 - 119 mg/L | 9.42 | 4.88 | 20.5 | <0.0001 |
| CRP 120 - 179 mg/L | 11.9 | 6.05 | 26.3 | <0.0001 |
| CRP 180 - 249 mg/L | 17.3 | 8.30 | 39.7 | <0.0001 |
| CRP >249 mg/L | 27.9 | 13.0 | 65.6 | 0.0000 |
| CRP not available | 5.63 | 2.99 | 12.0 | <0.0001 |
| IL6 <1.8 pg/mL (ref) |  |  |  |  |
| IL6 1.8 - 49 pg/mL | 0.58 | 0.16 | 3.77 | 0.48 |
| IL6 50 - 199 pg/mL | 3.94 | 1.13 | 24.9 | 0.068 |
| IL6 200 - 499 pg/mL | 12.9 | 3.43 | 84.7 | 0.001 |
| IL6 500 - 999 pg/mL | 27.5 | 5.45 | 219 | 0.0003 |
| IL6 >1000 pg/mL | 23.4 | 5.22 | 171 | 0.0002 |
| IL6 not available | 2.31 | 0.68 | 14.4 | 0.26 |
| Creatinine Normal (ref) |  |  |  |  |
| Creatinine >ULN | 3.72 | 2.87 | 4.83 | <0.0001 |
| Creatinine >2x ULN | 5.53 | 3.77 | 8.05 | <0.0001 |
| Creatinine >5x ULN | 4.47 | 2.47 | 7.83 | <0.0001 |
| Creatinine not available | 1.65 | 1.29 | 2.11 | 0.0001 |
| AST Normal (ref) |  |  |  |  |
| AST >ULN | 1.65 | 1.25 | 2.16 | 0.0004 |
| AST >2x ULN | 2.17 | 1.42 | 3.25 | 0.0002 |
| AST >5x ULN | 4.22 | 1.65 | 10.20 | 0.002 |
| AST >10x ULN | 41.2 | 6.97 | 780 | 0.0006 |
| AST >20x ULN | 6.86 | 0.82 | 57.6 | 0.055 |
| AST not available | 1.25 | 0.99 | 1.58 | 0.058 |
| ALT Normal (ref) |  |  |  |  |
| ALT >ULN | 0.77 | 0.55 | 1.05 | 0.11 |
| ALT >2x ULN | 1.30 | 0.74 | 2.17 | 0.34 |
| ALT >5x ULN | 3.08 | 1.13 | 7.73 | 0.020 |
| ALT not available | 1.02 | 0.83 | 1.26 | 0.83 |
| GGT Normal (ref) |  |  |  |  |
| GGT >ULN | 1.28 | 0.93 | 1.76 | 0.12 |
| GGT >2x ULN | 1.86 | 1.28 | 2.65 | 0.0008 |
| GGT >5x ULN | 3.02 | 1.65 | 5.32 | 0.0002 |
| GGT >10x ULN | 9.10 | 4.49 | 18.9 | <0.0001 |
| GGT not available | 1.24 | 0.99 | 1.56 | 0.066 |
| Ketone Bodies Negative - (ref) |  |  |  |  |
| Ketone Bodies Positive + | 0.89 | 0.55 | 1.38 | 0.60 |
| Ketone Bodies Positive ++ | 0.45 | 0.15 | 1.04 | 0.09 |
| Ketone Bodies Positive +++ | 0.40 | 0.10 | 1.16 | 0.14 |
| Ketone Bodies not available | 0.74 | 0.59 | 0.92 | 0.007 |

OR, odds ratio; CI, confidence interval

**Suppl. Table 3.** Multivariable relationships of anthropometrics, comorbidities and laboratory parameters with COVID-19-related mortality

| **Characteristics OR Lower Upper**  **95% CI 95% CI p** | | | | |
| --- | --- | --- | --- | --- |
| Age 18-25 years | 0.00 | 0.00 | 0.00 | 0.96 |
| Age 36-45 years | 0.90 | 0.19 | 4.71 | 0.89 |
| Age 46-55 years | 2.38 | 0.79 | 10.3 | 0.17 |
| Age 56-65 years | 5.52 | 1.95 | 23.3 | 0.005 |
| Age 66-75 years | 8.99 | 3.17 | 37.9 | 0.0003 |
| Age 76-85 years | 14.8 | 5.23 | 62.4 | <0.0001 |
| Age >85 years | 41.2 | 14.1 | 176 | <0.0001 |
| Sex male | 1.61 | 1.26 | 2.07 | 0.0002 |
| BMI 25 - 29.9 (kg∙m-2) | 0.99 | 0.75 | 1.30 | 0.92 |
| BMI 30 - 34.9 (kg∙m-2) | 1.01 | 0.72 | 1.39 | 0.97 |
| BMI >= 35 (kg∙m-2) | 1.54 | 1.02 | 2.31 | 0.038 |
| Diabetes | 1.57 | 1.08 | 2.28 | 0.018 |
| Insulin | 0.96 | 0.61 | 1.50 | 0.85 |
| Insulin unknown | 1.48 | 0.71 | 3.04 | 0.29 |
| Metformin | 0.66 | 0.41 | 1.04 | 0.080 |
| Sulfonylureas | 0.36 | 0.05 | 1.45 | 0.21 |
| GLP-1 Analogs | 0.55 | 0.14 | 1.70 | 0.33 |
| DPP4-Inhibitors | 0.68 | 0.33 | 1.36 | 0.29 |
| SGLT2-Inhibitors | 1.04 | 0.37 | 2.63 | 0.93 |
| HbA1c 6.4% - 8% | 2.53 | 0.92 | 7.96 | 0.089 |
| HbA1c 8.1% - 10% | 3.72 | 1.19 | 12.7 | 0.028 |
| HbA1c >10% | 6.23 | 1.79 | 23.3 | 0.005 |
| HbA1c not available | 4.36 | 1.73 | 12.9 | 0.004 |
| CRP 3- 29 mg/L | 2.10 | 1.01 | 4.92 | 0.064 |
| CRP 30 - 69 mg/L | 4.23 | 2.02 | 9.97 | 0.0003 |
| CRP 70 - 119 mg/L | 5.71 | 2.72 | 13.5 | <0.0001 |
| CRP 120 - 179 mg/L | 6.56 | 3.01 | 15.9 | <0.00001 |
| CRP 180 - 249 mg/L | 7.50 | 3.19 | 19.3 | <0.00001 |
| CRP > 249 mg/L | 12.9 | 5.24 | 34.4 | <0.00001 |
| CRP not available | 5.13 | 2.06 | 14.0 | 0.0008 |
| IL6 1.8 - 49 pg/mL | 0.290 | 0.06 | 2.20 | 0.16 |
| IL6 50 - 199 pg/mL | 0.88 | 0.19 | 6.65 | 0.89 |
| IL6 200 - 499 pg/mL | 1.98 | 0.39 | 15.7 | 0.45 |
| IL6 500 - 999 pg/mL | 6.11 | 0.89 | 61.1 | 0.086 |
| IL6 >1000 pg/mL | 5.92 | 0.96 | 53.4 | 0.075 |
| IL6 not available | 0.81 | 0.18 | 6.00 | 0.81 |
| Creatinine >ULN | 1.74 | 1.26 | 2.40 | 0.0007 |
| Creatinine >2x ULN | 1.68 | 1.03 | 2.71 | 0.035 |
| Creatinine >5x ULN | 1.69 | 0.78 | 3.60 | 0.17 |
| Creatinine not available | 1.28 | 0.67 | 2.37 | 0.44 |
| AST >ULN | 1.38 | 0.97 | 1.97 | 0.073 |
| AST >2x ULN | 1.54 | 0.80 | 2.94 | 0.20 |
| AST >5x ULN | 1.41 | 0.36 | 5.27 | 0.61 |
| AST >10x ULN | 13.0 | 0.83 | 552 | 0.12 |
| AST >20x ULN | 3.95 | 0.11 | 249 | 0.49 |
| AST not available | 0.86 | 0.51 | 1.43 | 0.56 |
| ALT >ULN | 0.67 | 0.42 | 1.03 | 0.071 |
| ALT >2x ULN | 0.98 | 0.42 | 2.24 | 0.97 |
| ALT >5x ULN | 1.44 | 0.23 | 7.69 | 0.69 |
| ALT not available | 1.34 | 0.76 | 2.37 | 0.31 |
| GGT >ULN | 1.10 | 0.74 | 1.61 | 0.64 |
| GGT >2x ULN | 1.11 | 0.69 | 1.77 | 0.67 |
| GGT >5x ULN | 1.25 | 0.60 | 2.52 | 0.53 |
| GGT >10x ULN | 4.36 | 1.62 | 12.1 | 0.004 |
| GGT not available | 0.93 | 0.57 | 1.48 | 0.76 |
| Ketone Bodies Positive + | 1.16 | 0.67 | 1.97 | 0.60 |
| Ketone Bodies Positive ++ | 0.59 | 0.18 | 1.60 | 0.34 |
| Ketone Bodies Positive +++ | 0.51 | 0.11 | 1.72 | 0.33 |
| Ketone Bodies not available | 0.89 | 0.66 | 1.18 | 0.40 |
| Hypertension | 1.22 | 0.94 | 1.59 | 0.13 |
| Coronary Artery Disease | 1.10 | 0.82 | 1.45 | 0.53 |
| Chronic Kidney Disease | 1.18 | 0.87 | 1.59 | 0.28 |
| Chronic Liver Disease | 1.78 | 0.92 | 3.30 | 0.074 |
| Liver Cirrhosis | 2.03 | 0.75 | 5.26 | 0.15 |

OR, odds ratio; CI, confidence interval

**Suppl. Table 4.** Characteristics of the patients with COVID-19 divided in three age groups

| **Characteristics** | **Recovered**  **(Young/Middle-aged)** | **Died**  **(Young/Middle-aged)** | **Recovered**  **(Older)** | **Died**  **(Older)** | **Recovered**  **(Old)** | **Died**  **(Old)** |
| --- | --- | --- | --- | --- | --- | --- |
| **Total** | 1035 (96.91 %) | 33 (3.09 %) | 1024 (83.93 %) | 196 (16.07 %) | 602 (68.8 %) | 273 (31.2 %) |
| **Age** |  |  |  |  |  |  |
| Age 18-25 (years) | 71 (100 %) | 0 (0 %) |  |  |  |  |
| Age 26-35 (years) | 199 (98.51 %) | 3 (1.49 %) |  |  |  |  |
| Age 36-45 (years) | 290 (98.64 % | 4 (1.36 %) |  |  |  |  |
| Age 46-55 (years) | 475 (94.81 %) | 26 (5.19 %) |  |  |  |  |
| Age 56-65 (years) |  |  | 578 (87.44 %) | 83 (12.56 %) |  |  |
| Age 66-75 (years) |  |  | 446 (79.79 %) | 113 (20.21 %) |  |  |
| Age 76-85 (years) |  |  |  |  | 478 (73.88 %) | 169 (26.12 %) |
| Age >85 (years) |  |  |  |  | 124 (54.39 %) | 104 (45.61 %) |
| **Sex** |  |  |  |  |  |  |
| Male | 645 (95.84 %) | 28 (4.16 %) | 655 (83.23 %) | 132 (16.77 %) | 302 (63.85 %) | 171 (36.15 %) |
| Female | 390 (98.73 %) | 5 (1.27 %) | 369 (85.22 %) | 64 (14.78 %) | 300 (74.63 %) | 102 (25.37 %) |
| BMI |  |  |  |  |  |  |
| 18.5 -24.9 (kg‧m-2) | 352 (98.6 %) | 5 (1.4 %) | 276 (85.98 %) | 45 (14.02 %) | 245 (67.68 %) | 117 (32.32 %) |
| 25 - 29.9 (kg‧m-2) | 369 (97.11 %) | 11 (2.89 %) | 390 (85.15 %) | 68 (14.85 %) | 218 (68.77 %) | 99 (31.23 %) |
| 30 - 34.9 (kg‧m-2) | 198 (96.12 %) | 8 (3.88 %) | 230 (85.82 %) | 38 (14.18 %) | 106 (68.83 %) | 48 (31.17 %) |
| ≥35 (kg‧m-2) | 116 (92.8 %) | 9 (7.2 %) | 128 (73.99 %) | 45 (26.01 %) | 33 (78.57 %) | 9 (21.43 %) |
| **Diabetes Status** |  |  |  |  |  |  |
| No Diabetes | 939 (97.51 %) | 24 (2.49 %) | 746 (85.75 %) | 124 (14.25 %) | 434 (70.11 %) | 185 (29.89 %) |
| Diabetes | 96 (91.43 %) | 9 (8.57 %) | 278 (79.43 %) | 72 (20.57 %) | 168 (65.62 %) | 88 (34.38 %) |
| **HbA1c** |  |  |  |  |  |  |
| <6.4 (%) | 6 (85.71 %) | 1 (14.29 %) | 21 (95.45 %) | 1 (4.55 %) | 21 (84 %) | 4 (16 %) |
| 6.4 – 8 (%) | 18 (90 %) | 2 (10 %) | 64 (85.33 %) | 11 (4.67 %) | 36 (72 %) | 14 (28 %) |
| 0.1 – 10 (%) | 11 (91.67 %) | 1 (8.33 %) | 36 (85.71 %) | 6 (14.29 %) | 14 (66.67 %) | 7 (33.33 %) |
| >10 (%) | 10 (90.91 %) | 1 (9.09 %) | 15 (62.5 %) | 9 (37.5 %) | 5 (71.43 %) | 2 (28.57 %) |
| unknown: | 990 (97.25 %) | 28 (2.75 %) | 888 (84.01 %) | 169 (15.99 %) | 526 (68.13 %) | 246 (31.87 %) |
| **Hypertension** |  |  |  |  |  |  |
| Yes | 212 (92.98 %) | 16 (7.02 %) | 585 (81.14 %) | 136 (18.86 %) | 448 (67.88 %) | 212 (32.12 %) |
| No | 823 (97.98 %) | 17 (2.02 %) | 439 (87.98 %) | 60 (12.02 %) | 154 (71.63 %) | 61 (28.37 %) |
| **Coronary Artery Dis.** |  |  |  |  |  |  |
| Yes | 22 (84.62 %) | 4 (15.38 %) | 147 (80.77 %) | 35 (19.23 %) | 152 (63.6 %) | 87 (36.4 %) |
| No | 1013 (97.22 %) | 29 (2.78 %) | 877 (84.49 %) | 161 (15.51 %) | 450 (70.75 %) | 186 (29.25 %) |
| **Chronic Kidney Dis.** |  |  |  |  |  |  |
| Yes | 46 (88.46 %) | 6 (11.54 %) | 123 (75 %) | 41 (25 %) | 170 (63.91 %) | 96 (36.09 %) |
| No | 989 (97.34 %) | 27 (2.66 %) | 901 (85.32 %) | 155 (14.68 %) | 432 (70.94 %) | 177 (29.06 %) |
| **Chronic Liver Dis.** |  |  |  |  |  |  |
| Yes | 20 (95.24 %) | 1 (4.76 %) | 25 (71.43 %) | 10 (28.57 %) | 10 (55.56 %) | 8 (44.44 %) |
| No | 1015 (96.94 %) | 32 (3.06 %) | 999 (84.3 %) | 186 (15.7 %) | 592 (69.08 %) | 265 (30.92 %) |
| **Liver Cirrhosis** |  |  |  |  |  |  |
| Yes | 6 (100 %) | 0 (0 %) | 9 (60 %) | 6 (40 %) | 3 (50 %) | 3 (50 %) |
| No | 1029 (96.89 %) | 33 (3.11 %) | 1015 (84.23 %) | 190 (15.77 %) | 599 (68.93 %) | 270 (31.07 %) |

**Suppl. Table 5.** Multivariable relationships of selected anthropometrics, comorbidities and laboratory parameters with COVID-19-related mortality in 3 age groups

| **Young/Middle-aged Older Old** | | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Characteristics** | **OR** | **p** | **OR** | **p** | **OR** | **P** |
| Sex female (ref) |  |  |  |  |  |  |
| Sex male | 3.07 | 0.027 | 1.27 | 0.18 | 1.58 | 0.0031 |
| BMI 18.5 - 24.9 (ref) |  |  |  |  |  |  |
| BMI 25 - 29.9 | 1.94 | 0.24 | 0.99 | 0.98 | 0.92 | 0.61 |
| BMI 30 - 34.9 | 2.53 | 0.12 | 0.90 | 0.67 | 0.93 | 0.73 |
| BMI ≥35 | 4.67 | 0.013 | 2.02 | 0.0059 | 0.57 | 0.16 |
| No Diabetes (ref) |  |  |  |  |  |  |
| Diabetes | 1.66 | 0.39 | 1.41 | 0.11 | 1.48 | 0.042 |
| HbA1c <6.4% (ref) |  |  |  |  |  |  |
| HbA1c 6.4% - 8 % | 0.92 | 0.95 | 4.72 | 0.15 | 2.14 | 0.23 |
| HbA1c 8.1% - 10% | 1.09 | 0.96 | 4.91 | 0.16 | 2.97 | 0.13 |
| HbA1c >10% | 1.11 | 0.95 | 19.5 | 0.0079 | 2.62 | 0.35 |
| HbA1c unknown | 0.93 | 0.95 | 10.1 | 0.027 | 3.77 | 0.022 |
| No Hypertension (ref) |  |  |  |  |  |  |
| Hypertension | 1.73 | 0.20 | 1.46 | 0.038 | 1.16 | 0.42 |
| No Coronary Artery Dis. (ref) |  |  |  |  |  |  |
| Coronary Artery Dis. | 2.60 | 0.15 | 1.13 | 0.58 | 1.19 | 0.29 |
| No Chronic Kidney Dis. (ref) |  |  |  |  |  |  |
| Chronic Kidney Dis. | 2.37 | 0.15 | 1.75 | 0.0091 | 1.32 | 0.089 |
| No Liver Cirrhosis (ref) |  |  |  |  |  |  |
| Liver Cirrhosis | 0.00 | 0.99 | 3.35 | 0.029 | 1.58 | 0.58 |

**Suppl. Table 6.** Multivariable relationships of selected anthropometrics, comorbidities and laboratory parameters with severity of COVID-19 in 3 age groups


| **Characteristics OR Lower Upper p**  **95%CI 95%CI** | | | | |
| --- | --- | --- | --- | --- |
| Young/Middle-aged - no Obesity, no Diabetes, no Hypertension (ref.) (N=593) |  |  |  |  |
| Young/Middle-age - Obesity, no Diabetes, no Hypertension (N=195) | 2.28 | 0.95 | 5.50 | 0.06 |
| Young/Middle-aged - Obesity, Diabetes, no Hypertension (N=24) | 5.34 | 2.33 | 13.5 | 0.0002 |
| Young/Middle-aged - Obesity, Diabetes, Hypertension (N=31) | 2.60 | 1.87 | 3.64 | <0.0001 |
| Older - no Obesity, no Diabetes, no Hypertension (N=339) | 2.66 | 2.01 | 3.52 | <0.0001 |
| Older - Obesity, no Diabetes, no Hypertension (N=92) | 16.02 | 5.16 | 71.0 | <0.0001 |
| Older - Obesity, Diabetes, no Hypertension (N=28) | 8.45 | 5.03 | 14.7 | <0.0001 |
| Older - Obesity, Diabetes, Hypertension (N=148) | 4.26 | 2.68 | 6.88 | <0.0001 |
| Old - no Obesity, no Diabetes, no Hypertension (N=166) | 5.41 | 3.67 | 8.07 | <0.0001 |
| Old - Obesity, no Diabetes, no Hypertension (N=25) | 4.11 | 0.85 | 29.3 | 0.10 |
| Old - Obesity, Diabetes, no Hypertension (N=7) | 4.84 | 2.65 | 9.07 | <0.0001 |
| Old - Obesity, Diabetes, Hypertension (N=80) | 12.32 | 4.55 | 43.0 | <0.0001 |
| Sex Male | 1.56 | 1.27 | 1.94 | <0.0001 |
| HbA1c 6.4% - 8% | 1.68 | 0.50 | 5.21 | 0.38 |
| HbA1c 8.1% - 10% | 1.81 | 0.49 | 6.49 | 0.36 |
| HbA1c >10% | 1.33 | 0.28 | 6.78 | 0.72 |
| HbA1c unknown | 1.28 | 0.41 | 3.53 | 0.65 |
| Coronary Artery Disease | 1.01 | 0.66 | 1.56 | 0.97 |
| Chronic Kidney Disease | 1.63 | 1.08 | 2.49 | 0.02 |
| Liver Cirrhosis | 0.34 | 0.10 | 1.05 | 0.07 |

**Suppl. Table 7.** Multivariable relationships of four age groups based on the presence (unhealthy) or absence (healthy) of obesity, diabetes and hypertension and selected anthropometrics, comorbidities and laboratory parameters with COVID-19-related mortality


| **Model 1**  **Characteristics OR Lower Upper p**  **95%CI 95%CI** | | | | |
| --- | --- | --- | --- | --- |
| Young - no Obesity, no Diabetes, no Hypertension (ref.) (N=203) |  |  |  |  |
| Young - Obesity, no Diabetes, no Hypertension (N=50) | 0.0003 | - | - | 0.98 |
| Young - Obesity, Diabetes, no Hypertension (N=1) | 211 | 5.80 | 10741 | 0.002 |
| Young - Obesity, Diabetes, Hypertension (N=2) | 4.24 | 0.17 | 108 | 0.31 |
| Middle-aged - no Obesity, no Diabetes, no Hypertension (ref.) (N=390) | 4.12 | 0.75 | 76.7 | 0.18 |
| Middle-age - Obesity, no Diabetes, no Hypertension (N=145) | 9.32 | 0.36 | 244 | 0.12 |
| Middle-aged - Obesity, Diabetes, no Hypertension (N=23) | 14.34 | 1.31 | 319 | 0.03 |
| Middle-aged - Obesity, Diabetes, Hypertension (N=29) | 5.72 | 0.84 | 113 | 0.12 |
| Older - no Obesity, no Diabetes, no Hypertension (N=339) | 25.2 | 5.40 | 449 | 0.002 |
| Older - Obesity, no Diabetes, no Hypertension (N=92) | 40.2 | 5.82 | 804 | 0.001 |
| Older - Obesity, Diabetes, no Hypertension (N=28) | 54.2 | 11.0 | 981 | 0.0001 |
| Older - Obesity, Diabetes, Hypertension (N=148) | 23.5 | 4.39 | 435 | 0.003 |
| Old - no Obesity, no Diabetes, no Hypertension (N=166) | 74.4 | 15.87 | 1328 | <0.0001 |
| Old - Obesity, no Diabetes, no Hypertension (N=25) | 22.7 | 0.82 | 633 | 0.04 |
| Old - Obesity, Diabetes, no Hypertension (N=7) | 85.3 | 16.7 | 1562 | <0.0001 |
| Old - Obesity, Diabetes, Hypertension (N=80) | 90.4 | 15.16 | 1,735. | <0.0001 |
| Sex Male | 1.37 | 0.98 | 1.95 | 0.07 |
| HbA1c 6.4% - 8% | 1.41 | 0.38 | 6.82 | 0.63 |
| HbA1c 8.1% - 10% | 1.99 | 0.50 | 10.1 | 0.36 |
| HbA1c >10% | 3.47 | 0.67 | 20.8 | 0.15 |
| HbA1c unknown | 2.28 | 0.70 | 10.3 | 0.22 |
| Coronary Artery Disease | 1.13 | 0.70 | 1.79 | 0.60 |
| Chronic Kidney Disease | 1.77 | 1.16 | 2.69 | 0.008 |
| Liver Cirrhosis | 1.55 | 0.32 | 5.63 | 0.54 |

OR, odds ratio; CI, confidence interval; Model 1, adjusted for sex, HbA1c, coronary artery disease, chronic kidney disease and liver cirrhosis

**Suppl. Figure 1.** Study flow chart

****

**Suppl. Figure 2.** Multivariable relationships of selected anthropometrics, comorbidities and laboratory parameters with COVID-19-related mortality

****

**Legends of the supplemental figures**

**Suppl. Figure 1**

Study flow chart.

**Suppl. Figure 2**

Adjusted odds ratios and 95% confidence intervals of anthropometrics, sex, comorbidities and laboratory parameters with COVID-19-related mortality in 3163 patients. All parameters shown were included in the multivariate regression analysis.